We are happy to announce FDA approval of a new treatment for chronic graft-versus-host disease (GVHD), the most common long-term complication of allogeneic stem cell transplantation (allo-HSCT). Learn more. https://bit.ly/46MhOpr
Incyte Medical’s Post
More Relevant Posts
-
Ahead of print Differential expression of miRNA-769-5p and Smad2 in patients with or without oral cGVHD Oral chronic graft-versus-host disease (cGVHD) impacts quality of life of patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, its precise pathogenesis remains unknown, with potential associations with differential microRNA (miRNA) expression and the TGF-β/Smad signaling pathway. This study aims to explore miRNA expression profiles in the peripheral blood of oral cGVHD patients, focusing on miRNA-769-5p and its relationship with Smad2. https://lnkd.in/dcHbgAmm
To view or add a comment, sign in
-
Post-transplantation cyclophosphamide (PTCy) may be a superior option than rabbit anti-thymocyte globulin (rATG) for preventing #GVHD in adult recipients of peripheral blood allogeneic stem cell transplantation (allo-SCT) from matched, unrelated donors (MUD). Read more on Nucleus: https://ow.ly/ghPp50SiqI0
To view or add a comment, sign in
-
Oncology Rehabilitation Researcher | Focused on Real-World Evidence & Access | Director of Research at ReVital Cancer Rehabilitation | Creator of the EXCEEDS Algorithm
𝗖𝗮𝗻 𝗲𝘅𝗲𝗿𝗰𝗶𝘀𝗲 𝗶𝗻𝘁𝗲𝗿𝘃𝗲𝗻𝘁𝗶𝗼𝗻𝘀 𝗵𝗲𝗹𝗽 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝗰𝗮𝗻𝗰𝗲𝗿 𝘀𝘁𝗮𝘆 𝗼𝘂𝘁 𝗼𝗳 𝘁𝗵𝗲 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹? In a new systematic review and meta-analysis by Dr David Mizrahi PhD et al., exercise during treatment was found to 📉 reduce hospital length of stay by 𝟭.𝟰 𝗱𝗮𝘆𝘀 and 📉 reduce hospital admissions by 𝟴% for patients receiving hematopoietic stem cell transplantation. Takeaway: Incorporating exercise into multidisciplinary care plans for patients receiving HSCT may help them stay out of the hospital 🔗 https://lnkd.in/eZ8GqCaB
To view or add a comment, sign in
-
🔬 Jamy Reports Vedolizumab's Efficacy in Preventing aGVHD In Nature Medicine, Omer Jamy, M.D., Associate Professor in the UAB Division of Hematology and Oncology, and colleagues find that adding Vedolizumab to standard preventive therapy reduces the incidence of intestinal acute graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. Learn more ➡️ https://loom.ly/lncpU_4
To view or add a comment, sign in
-
Chronic Graft-Versus-Host disease (#GVHD) is a complex immune-mediated response. GVHD is a serious complication of allogeneic stem cell transplantation (alloSCT), where donor cells mount an immune response against the host's organs and tissues. The clinical presentation of GVHD is a constellation of symptoms across multiple organ systems. Learn more about this serious complication of alloSCT. https://bit.ly/3LGfRRy
Learn about Chronic Graft-Versus-Host Disease
To view or add a comment, sign in
-
One more success story - our stage IV disseminated medulloblastoma patient , is having a disease free survival post chemotherapy and stem cell transplantation. Pet comparison is here to show how the disease got scavenged by chemo . If you can make he was having disease in his bones and bone marrow, for the unversed this disease is supposed to be limited to brain , but in our case was disseminated to all his bones and bone marrow. With good planning and team work we achieved the impossible #medulloblastoma #Muktacancerclinic #Mukta-can-erase-cancer
To view or add a comment, sign in
-
I recently wrote a blog about the transformative potential of Hematopoietic Stem Cells (HSCs) and their growing impact on modern medicine. From pioneering treatments for leukemia and lymphoma to offering hope for autoimmune diseases and genetic disorders, HSCs are revolutionizing patient care. Key highlights from this blog: 🔬 Hematopoietic Stem Cell Transplantation (HSCT) is a vital therapy for hematological conditions, utilizing both autologous and allogeneic transplants to restore healthy blood systems. 🔬 Cutting-edge techniques, like the use of polyvinyl caprolactam (PCL) polymers, are overcoming previous limitations, improving patient outcomes, and expanding the availability of HSCs. 🔬 The future of HSC-based therapies looks bright, with personalized medicine on the horizon. Read more here! https://lnkd.in/eQg_TYVw
To view or add a comment, sign in
-
MD| MSC| MRCP UK [ESENeph]| RCPSC[SEAP]| AACMF[FPCT]WKA|ICOM| GIM , ADULT GENERAL CLINICAL NEPHROLOGY AND KIDNEY TRANSPLANT AT UNIVERSITY OF TORONTO
🔥🔥🔥Post-transplant lymphoproliferative disorder (PTLD) is a heterogeneous group of lymphoid malignant neoplasms arising after solid organ transplantation or haematopoietic stem cell transplantation. 💪💪💪🔥🔥🔥🔥🔥 🔥🔥🔥PTLD represents the second most common malignancy in transplanted patients.💪 🔥🔥🔥Despite achievements in diagnosis and treatment, PTLD remains a life-threatening complication that portends high morbidity and mortality.💪💪💪🔥🔥🔥🔥🔥 Treatment Algorithm for PTLD. Taken from NDTsocial 🔥🔥🔥Doi : 10.1093/ndt/gfz207🔥🔥🔥
To view or add a comment, sign in
-
Out of Vietnam, a small phase 1 study using patients own fat derived stem cells to combat inflamm-aging , which resulted in a reduction in various pro-inflammatory cytokines after 6 months. Safety and efficacy of autologous adipose tissue-derived stem cell transplantation in aging-related low-grade inflammation patients: a single-group, open-label, phase I clinical trial https://lnkd.in/e9mh325X
To view or add a comment, sign in
-
HepatoPredict, developed by Ophiomics, new prognostic tool supporting the decision of liver transplantation in hepatocellular carcinoma ♥️. 👉 https://kntn.ly/f9de9e16
To view or add a comment, sign in
2,924 followers
Director, Global Product Strategy, Incyte
2moGreat news!